CO6241121A2 - Derivados de azapeptidps - Google Patents

Derivados de azapeptidps

Info

Publication number
CO6241121A2
CO6241121A2 CO09141805A CO09141805A CO6241121A2 CO 6241121 A2 CO6241121 A2 CO 6241121A2 CO 09141805 A CO09141805 A CO 09141805A CO 09141805 A CO09141805 A CO 09141805A CO 6241121 A2 CO6241121 A2 CO 6241121A2
Authority
CO
Colombia
Prior art keywords
compound
azapeptidps
derivatives
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CO09141805A
Other languages
English (en)
Spanish (es)
Inventor
Scott Harbeson
Roger Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of CO6241121A2 publication Critical patent/CO6241121A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CO09141805A 2007-06-12 2009-12-11 Derivados de azapeptidps CO6241121A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29

Publications (1)

Publication Number Publication Date
CO6241121A2 true CO6241121A2 (es) 2011-01-20

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09141805A CO6241121A2 (es) 2007-06-12 2009-12-11 Derivados de azapeptidps

Country Status (26)

Country Link
US (4) US20090036357A1 (US20080242721A1-20081002-C00053.png)
EP (3) EP2003120B9 (US20080242721A1-20081002-C00053.png)
JP (1) JP2010529196A (US20080242721A1-20081002-C00053.png)
KR (2) KR101185899B1 (US20080242721A1-20081002-C00053.png)
CN (2) CN102424668A (US20080242721A1-20081002-C00053.png)
AR (1) AR066972A1 (US20080242721A1-20081002-C00053.png)
AT (2) ATE447554T1 (US20080242721A1-20081002-C00053.png)
AU (1) AU2008267048C1 (US20080242721A1-20081002-C00053.png)
BR (2) BRPI0813911A2 (US20080242721A1-20081002-C00053.png)
CA (1) CA2692028C (US20080242721A1-20081002-C00053.png)
CO (1) CO6241121A2 (US20080242721A1-20081002-C00053.png)
CY (1) CY1109766T1 (US20080242721A1-20081002-C00053.png)
DE (1) DE602008000255D1 (US20080242721A1-20081002-C00053.png)
DK (1) DK2003120T3 (US20080242721A1-20081002-C00053.png)
ES (3) ES2356334T3 (US20080242721A1-20081002-C00053.png)
HK (2) HK1136576A1 (US20080242721A1-20081002-C00053.png)
HR (1) HRP20100065T1 (US20080242721A1-20081002-C00053.png)
MX (1) MX2009013565A (US20080242721A1-20081002-C00053.png)
PL (1) PL2003120T3 (US20080242721A1-20081002-C00053.png)
PT (1) PT2003120E (US20080242721A1-20081002-C00053.png)
RS (1) RS51226B (US20080242721A1-20081002-C00053.png)
RU (2) RU2448958C2 (US20080242721A1-20081002-C00053.png)
SI (1) SI2003120T1 (US20080242721A1-20081002-C00053.png)
TW (1) TW200908970A (US20080242721A1-20081002-C00053.png)
WO (1) WO2008156632A1 (US20080242721A1-20081002-C00053.png)
ZA (1) ZA200909079B (US20080242721A1-20081002-C00053.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
US8784858B2 (en) * 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
DK3135656T3 (en) 2011-06-20 2019-04-23 H Lundbeck As DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
HRP20211687T1 (hr) * 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AR117600A1 (es) * 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206497B1 (en) 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
KR100333016B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
ATE282428T1 (de) 2001-05-03 2004-12-15 Hoffmann La Roche Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2458807A1 (en) * 2001-08-31 2003-03-13 Bristol-Myers Squibb Company Use of atazanavir in hiv therapy
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2516642C (en) 2003-02-21 2010-11-23 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CA2571726C (en) * 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008156632A1 (en) * 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
US8158805B2 (en) 2012-04-17
CN102424668A (zh) 2012-04-25
SI2003120T1 (sl) 2010-03-31
RS51226B (sr) 2010-12-31
RU2012101881A (ru) 2013-07-27
KR101185899B1 (ko) 2012-09-27
PL2003120T3 (pl) 2010-04-30
EP2116532A1 (en) 2009-11-11
RU2448958C2 (ru) 2012-04-27
HK1136576A1 (en) 2010-07-02
TW200908970A (en) 2009-03-01
ATE536343T1 (de) 2011-12-15
ES2356334T3 (es) 2011-04-07
AU2008267048C1 (en) 2013-01-17
CA2692028C (en) 2013-06-04
BRPI0813911A2 (pt) 2012-02-22
EP2003120B9 (en) 2010-06-02
EP2322509B1 (en) 2012-08-22
BRPI0823520A2 (pt) 2013-12-17
ZA200909079B (en) 2011-05-25
AU2008267048A1 (en) 2008-12-24
CA2692028A1 (en) 2008-12-24
PT2003120E (pt) 2010-02-11
ES2394952T3 (es) 2013-02-07
HK1127345A1 (en) 2009-09-25
DK2003120T3 (da) 2010-03-15
US20090036357A1 (en) 2009-02-05
KR20120029480A (ko) 2012-03-26
EP2003120B1 (en) 2009-11-04
ATE447554T1 (de) 2009-11-15
JP2010529196A (ja) 2010-08-26
MX2009013565A (es) 2010-06-02
HRP20100065T1 (hr) 2010-03-31
RU2010100821A (ru) 2011-07-20
US20120165288A1 (en) 2012-06-28
US20130041156A1 (en) 2013-02-14
AU2008267048B2 (en) 2012-05-31
CY1109766T1 (el) 2014-09-10
US20110009355A1 (en) 2011-01-13
KR20100020033A (ko) 2010-02-19
DE602008000255D1 (de) 2009-12-17
CN101711237B (zh) 2013-08-07
CN101711237A (zh) 2010-05-19
AR066972A1 (es) 2009-09-23
WO2008156632A1 (en) 2008-12-24
ES2395137T3 (es) 2013-02-08
EP2322509A1 (en) 2011-05-18
US8258309B2 (en) 2012-09-04
EP2116532B1 (en) 2011-12-07
EP2003120A1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
CO6241121A2 (es) Derivados de azapeptidps
CO6251287A2 (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato -842
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
EA201000113A1 (ru) Пиразольные соединения
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
ME01992B (me) Jedinjenje diarilhidantoina
EA200801381A1 (ru) Производные пиримидина
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200901039A1 (ru) Способ получения производного бензимидазола
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
CR7939A (es) Nueva modificacion cristalina del anhidrato de boscalida
CO5601027A2 (es) Derivados de imidazol-4-il-etinil-piridina
DOP2006000234A (es) Inhibidores de cinasa
ECSP088162A (es) Mezclas pesticidas que comprenden una fenilsemicarbazona
CO6251294A2 (es) Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer
AU2006232435A8 (en) BCRP/ABCG2 inhibitor
AR111806A1 (es) Derivados de indol n-sustituidos
AR083017A1 (es) Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
EA200801596A1 (ru) Новые 11-бета-гидроксиандроста-4-ен-3-оны

Legal Events

Date Code Title Description
FC Application refused